Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Share-based Compensation (2016 - 2025)

OptimizeRx (OPRX) has disclosed Share-based Compensation for 14 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 33.27% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, down 39.29% year-over-year, with the annual reading at $7.0 million for FY2025, 39.29% down from the prior year.
  • Share-based Compensation hit $2.0 million in Q4 2025 for OptimizeRx, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $13.2 million in Q4 2023 to a low of -$7.3 million in Q3 2023.
  • Historically, Share-based Compensation has averaged $2.7 million across 5 years, with a median of $2.8 million in 2024.
  • Biggest five-year swings in Share-based Compensation: soared 538.78% in 2022 and later crashed 271.68% in 2023.
  • Year by year, Share-based Compensation stood at $3.1 million in 2021, then soared by 36.4% to $4.3 million in 2022, then skyrocketed by 208.63% to $13.2 million in 2023, then plummeted by 77.71% to $2.9 million in 2024, then tumbled by 33.27% to $2.0 million in 2025.
  • Business Quant data shows Share-based Compensation for OPRX at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $1.5 million in Q2 2025.